Clinical Data Spyre drug for inflammatory bowel disease shows promise in early study BioPharma DiveThe therapy, which works similarly to Takeda s blockbuster Entyvio, showed remission rates that suggest a best-in-class profile, the company said.Clinical DataImmunology & InflammationRead full story pharminent April 13, 2026 (Last updated: April 14, 2026) BioPharma Dive The therapy, which works similarly to Takeda s blockbuster Entyvio, showed remission rates that suggest a best-in-class profile, the company said. Clinical DataImmunology & InflammationRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphomaNext: Alamar, Hemab, Kailera, and Seaport advance IPOs Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
